Iceland screens, treats, or prevents multiple myeloma (iStopMM): A population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies Journal Article
| Authors: | Rögnvaldsson, S.; Love, T. J.; Thorsteinsdottir, S.; Reed, E. R.; Óskarsson, J. Þ; Pétursdóttir, Í; Sigurðardóttir, G. Á; Viðarsson, B.; Önundarson, P. T.; Agnarsson, B. A.; Sigurðardóttir, M.; Þorsteinsdóttir, I.; Ólafsson, Í; Þórðardóttir, Á R.; Eyþórsson, E.; Jónsson, Á; Björnsson, A. S.; Gunnarsson, G. Þ; Pálsson, R.; Indriðason, Ó S.; Gíslason, G. K.; Ólafsson, A.; Hákonardóttir, G. K.; Brinkhuis, M.; Halldórsdóttir, S. L.; Ásgeirsdóttir, T. L.; Steingrímsdóttir, H.; Danielsen, R.; Dröfn Wessman, I.; Kampanis, P.; Hulcrantz, M.; Durie, B. G. M.; Harding, S.; Landgren, O.; Kristinsson, S. Y. |
| Article Title: | Iceland screens, treats, or prevents multiple myeloma (iStopMM): A population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
| Abstract: | Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy. © 2021, The Author(s). |
| Journal Title: | Blood Cancer Journal |
| Volume: | 11 |
| Issue: | 5 |
| ISSN: | 2044-5385 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2021-05-17 |
| Start Page: | 94 |
| Language: | English |
| DOI: | 10.1038/s41408-021-00480-w |
| PROVIDER: | scopus |
| PMCID: | PMC8128921 |
| PUBMED: | 34001889 |
| DOI/URL: | |
| Notes: | Malin Hultcrantz's last name is misspelled on the original publication -- Erratum issued, see DOI: [10.1038/s41408-023-00814-w] -- Article -- Export Date: 1 June 2021 -- Source: Scopus |
